Delivery Order SPE2DB20D9127-SPE2DB24FPQG7
Award Date 3/29/24
Potential Completion Date 4/19/24
Potential Value $52K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $51,581.80 contract is for the delivery of TYSABRI 300 MG/15 ML vials to support the medical supply needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which allows...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a $41,265.44 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Tysabri 300 mg/15 ml vials over a period ending on May 15, 2024. This delivery order was issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
- This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the supply of the pharmaceutical product TYSABRI 300 MG/15 ML VIAL 15ML. The total potential value of the contract is $10,316.36, with a completion date of January 29, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that provides a range of pharmaceutical and medical supplies to the...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,158.18 order is for TYSABRI 300 MG/15 ML VIAL 15ML, a biologic medication. The order has a completion date of July 22, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,262.76 to DMS Pharmaceutical Group Inc. on August 18, 2025, for the supply of TYSABRI 300 mg/15 ml vials. This firm fixed-price delivery order is scheduled for completion by September 9, 2025, with performance taking place at the vendor's facility in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its status as a woman-owned...
- This is a delivery order valued at $10,316.36 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of Tysabri 300 mg/15 ml vials with a completion date of June 11, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to DMS Pharmaceutical Group by the DLA under the SPE2DB program, valued at up to $499,999,999 through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $52,627.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of TYSABRI 300 mg/15 mL vials. This firm fixed-price delivery order, issued on September 25, 2025, with an ultimate completion date of October 17, 2025, represents a specific procurement action under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award, valued at $15,474.54, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of Tysabri 300 mg/15 ml vials. The contract is a firm fixed-price delivery order with no set-aside designation. It is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $59,611.44, is for the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid...
- This federal contract award was issued by the Defense Logistics Agency's (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $41,265.44 firm fixed-price delivery order is for the supply of TYSABRI 300 MG/15 ML vials to support the recurring medical needs of military health facilities. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the...